Nice.
Finally more proof of things going in the right direction ( at S N A I L pace though ).
Given that the partners ( Sandoz ) had previously ordered Vitaros units for two of those newly approved countries. That should mean that National approvals should be in the process for at least Denmark and Norway. And these two countries should be the first to launch, out of the newly approved countries.
That would make Vitaros approved in 23 Countries in the world.
Worth to note is the Emphasis on the 2Q having at least double Vitaros sales versus the 1Q "poor" numbers.
"Since the first European approval of Vitaros in 2013, together with our commercial partners, we have made significant progress in making Vitaros available to men suffering from erectile dysfunction in Europe. These additional approvals, under the DCP, further enhance the value of Vitaros for our partners and potentially our shareholders," said Richard W. Pascoe, Chief Executive Officer of Apricus. "Vitaros has a unique product profile that meets the needs of a large number of patients suffering from erectile dysfunction to include those patients who are intolerant to or do not respond to current treatment options. With its rapid onset of action and unique topical delivery, we believe that Vitaros will capture a significant share of the approximately $1 billion PDE-5 inhibitor market in Europe."
"Moreover, with the recent successful launches in Spain and France, Vitaros unit sales in Europe more than doubling from the first quarter of 2015 to the second quarter of 2015, and an expected launch in Italy later this year, we are confident that Vitaros will continue to generate meaningful revenue for Apricus to help advance our clinical-stage pipeline."
|
